Test Price
2,800 AED✅ Home Collection Available
C15orf41 Gene Congenital Dyserythropoietic Anemia Type 1B (CDAIB) Next-Generation Sequencing (NGS) Genetic Test in UAE | 2,800 AED | DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited processing and rigorous bioinformatics pipelines for single nucleotide variants, indels, and copy-number alterations within the C15orf41 coding region.
- Premium Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all Emirates.
- Clinical Guidance: Complimentary telephonic post-test result interpretation by a DHA-licensed consultant medical geneticist.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
- Corporate Lab: DNA Labs UAE | DHA Facility License No. 1143.
Test Overview & Methodology
This sensitive, multi-exon next-generation sequencing test analyzes the entire coding region and splice junctions of the C15orf41 (CDAN1) gene to identify pathogenic variants responsible for congenital dyserythropoietic anemia type 1B. The assay provides definitive molecular diagnosis, carrier detection, and informs family planning and prenatal screening decisions for affected families across the UAE.
| Feature | NGS Panel – DNA Labs UAE | Alternative – Sanger Sequencing |
|---|---|---|
| Analytical Sensitivity | 99.9% for SNVs, indels, and CNVs across all coding exons | ~98% per amplicon; incapable of detecting large deletions or duplications |
| Methodology | Massively parallel next-generation sequencing with deep coverage (≥100×) and variant confirmation via orthogonal chemistry | Targeted PCR amplification followed by capillary electrophoresis; single-exon focus only |
| Turnaround Time | 21–28 calendar days (3–4 weeks) | 42–56 calendar days (6–8 weeks) |
Physician Insight & Safety Protocols
“The C15orf41 NGS test is a critical tool for confirming CDA type 1B in patients presenting with refractory anemia, ineffective erythropoiesis, and characteristic bone marrow morphology. However, results must always be correlated with complete blood counts, reticulocyte indices, and family segregation studies. A negative report does not exclude other congenital dyserythropoietic anemia subtypes or acquired mimics, and comprehensive clinical follow-up remains indispensable.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication & Clinical Precautions
This genetic test is a diagnostic aid and does not replace ongoing medical management. Patients should not discontinue, alter, or initiate any prescribed therapy—including iron chelation, folic acid supplementation, or transfusion regimens—without consulting their attending hematologist. Test results should be reviewed in conjunction with a comprehensive clinical evaluation.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: No absolute contraindications. Temporarily defer collection if the patient has an acute febrile illness, active hemolytic crisis requiring hospitalization, or recent blood transfusion within the past 14 days (may mask underlying genetic markers).
- Emergency Red Flags: Sudden severe pallor, jaundice with dark urine, acute respiratory distress, rapidly enlarging splenomegaly with abdominal pain, or signs of hemolytic shock—seek emergency medical care immediately.
- Sample Adequacy: The laboratory may reject specimens with insufficient DNA yield, clotted whole blood, or degraded nucleic acid. A replacement sample may be requested at no additional charge.
Patient FAQ & Clinical Guidance
1. What is the C15orf41 genetic test used for?
This test identifies disease-causing mutations in the C15orf41 gene, which are responsible for congenital dyserythropoietic anemia type 1B (CDAIB). It is indicated for patients with unexplained chronic anemia, ineffective erythropoiesis, and characteristic bone marrow findings. The test enables precise molecular diagnosis, carrier detection, and informed family planning.
2. How is the sample collected, and what options are available?
Our DHA-licensed phlebotomists collect 2–3 mL of whole blood in an EDTA tube via VIP mobile phlebotomy at your home or office. Alternatively, a buccal swab or FTA card may be submitted. All specimens are transported under strict temperature-controlled cold-chain conditions to preserve DNA integrity. Home collection is available daily from 8 AM to 11 PM.
3. What is the turnaround time and total cost?
The total cost is 2,800 AED. Results are typically delivered within 21 to 28 calendar days (3–4 weeks) from sample accession. Expedited reporting may be available upon request. A complimentary post-test genetic counselling session with a consultant medical geneticist is included to explain the findings and guide clinical decision-making.
4. Who should consider this genetic test?
This test is recommended for individuals with suspected congenital dyserythropoietic anemia based on clinical and laboratory findings, including unexplained normocytic or macrocytic anemia, elevated serum ferritin, indirect hyperbilirubinemia, and bone marrow aspirate showing erythroid hyperplasia with binuclearity. It is also offered for at-risk family members and for prenatal diagnosis in consanguineous pedigrees.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License No. 1143 and complies with all applicable UAE federal data protection and health information governance frameworks. Patient genetic data is processed, stored, and transmitted in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Consent for genetic testing and data processing is obtained prior to sample collection, and all clinical safety and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Results are released exclusively to the ordering physician or the patient upon verified identity confirmation.
Clinical & Logistical Metadata
| Test Name | C15orf41 Gene Congenital Dyserythropoietic Anemia Type 1B (CDAIB) Next-Generation Sequencing (NGS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 calendar days (3–4 weeks) |
| Sample Type / Matrix | Whole blood (EDTA), buccal swab, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) with deep coverage ≥100×, including orthogonal variant confirmation |
| ICD-10-CM Code | D61.09 |
| LOINC Code | 21665-5 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians